[The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
The presence of aluminum bone disease can be predicted by a rise in serum aluminum of > or = 50 microg/L following DFO challenge combined with plasma levels of intact PTH of < 150 pg/mL. However, the gold standard for the diagnosis of aluminum bone disease is a bone biopsy showing adynamic bone or osteomalacia. The dialysate concentration of aluminum should be maintained at < 10 microg/L and baseline levels of serum aluminum should be < 20 microg/L. In symptomatic patients with serum aluminum levels > 60 microg/L but < 200 microg/L or a rise of aluminum after DFO > 50 microg/L, DFO should be given to treat the aluminum overload.
Nakazawa
Ryoichi
R
Department of Nephrology, Tokatsu Clinic Hospital.
D000535:Aluminum / Q000009:adverse effects* / Q000032:analysis / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001851:Bone Diseases, Metabolic / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy*; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D017583:Hemodiafiltration; D015312:Hemodialysis Solutions / Q000737:chemistry; D006801:Humans; D008567:Membranes, Artificial; D010281:Parathyroid Hormone / Q000097:blood; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods
D015415:Biomarkers; D015312:Hemodialysis Solutions; D008567:Membranes, Artificial; D010281:Parathyroid Hormone; D000535:Aluminum; D003676:Deferoxamine